Customize your JAMA Network experience by selecting one or more topics from the list below.
Regulatory approval of currently available drug-eluting coronary stents was granted on the basis of results from relatively small clinical trials that enrolled highly selected patients. To assess outcomes in patients who are representative of “real world” clinical practice, investigators from the 5-center Danish Organization on Randomized Trials with Clinical Outcome (SORT OUT II) study randomly assigned 2098 patients undergoing primary coronary intervention to receive either sirolimus-eluting or paclitaxel-eluting stents to treat target lesions. Galløe and colleagues Article report that there were no significant differences in the composite clinical end point of either cardiac death, acute myocardial infarction (AMI),
target lesion revascularization, or target vessel revascularization,
or the secondary end points of total and cardiac mortality, AMI, or stent thrombosis among patients receiving either the sirolimus-eluting or paclitaxel-eluting stent. In an editorial, Mukherjee and Moliterno Article discuss the contributions and limitations of the SORT OUT II trial results for determining safe and effective revascularization practices.
This Week in JAMA . JAMA. 2008;299(4):385. doi:10.1001/jama.299.4.385
Create a personal account or sign in to: